| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Mar―23 |
Novel Benzosuberone/Indanone-Linked Thiazoles as Small-Molecule SARS-CoV-2 Main Protease Inhibitors |
Thoraya A. Farghaly, Elham N. Bifari, Mariam A. Al-sheikh, Afaf Y. Khormi, Hanadi Y. Medrasi, Jihan Qurban, Hanan Gaber Abdulwahab |
| 2 |
[GO] |
2023―May―11 |
Identification of potential targets against SARS-CoV-2 of antiviral drugs based on photoaffinity probes |
Yuexiang Ma, Jin Wang, Xiaoyan Pan, Jie Zhang, Yuanyuan Shan |
| 3 |
[GO] |
2022―Aug―22 |
Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion |
Carlos A. Fuzo, Ronaldo B. Martins, Thais F. C. Fraga-Silva, Martin K. Amstalden, Thais Canassa De Leo, Juliano P. Souza, Thais M. Lima, Lucia H. Faccioli, Débora Noma Okamoto, Maria Aparecida Juliano, Suzelei C. França, Luiz Juliano, Vania L. D. Bonato, Eurico Arruda, Marcelo Dias-Baruffi |
| 4 |
[GO] |
2022―Jun―25 |
The potential of developing a protective peptide-based vaccines against SARS-CoV-2 |
Ahmed O. Shalash, Istvan Toth, Mariusz Skwarczynski |
| 5 |
[GO] |
2022―Jun―16 |
Papaverine, a promising therapeutic agent for the treatment of COVID-19 patients with underlying cardiovascular diseases (CVDs) |
Mehdi Valipour, Hamid Irannejad, Saeed Emami |
| 6 |
[GO] |
2021―Nov―11 |
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review |
Suwen Hu, Songwei Jiang, Xiang Qi, Renren Bai, Xiang-Yang Ye, Tian Xie |
| 7 |
[GO] |
2021―Jul―29 |
Emerging cases of mucormycosis under
COVID
-19 pandemic in India: Misuse of antibiotics |
Gaurav Gupta, Roshan S., Yogendra Singh, Lakshmi Thangavelu, Sachin Kumar Singh, Harish Dureja, Dinesh Kumar Chellappan, Kamal Dua |
| 8 |
[GO] |
2021―Apr―13 |
Potential antiviral activity of isorhamnetin against
SARS-CoV
-2 spike pseudotyped virus in vitro |
Yingzhuan Zhan, Wenjing Ta, Wenjuan Tang, Ruochen Hua, Jue Wang, Cheng Wang, Wen Lu |
| 9 |
[GO] |
2021―Apr―03 |
TWIRLS
, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via
ACE2 |
|
| 10 |
[GO] |
2020―Nov―30 |
Review of registered clinical trials for the treatment of COVID-19 |
Fatemeh Babaei, Mohammadreza Mirzababaei, Marjan Nassiri-Asl, Hossein Hosseinzadeh |
| 11 |
[GO] |
2020―Nov―15 |
CB2
receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in
SARS-CoV
-2 infections |
M. F. Meeran, Charu Sharma, Sameer N. Goyal, Sanjay Kumar, Shreesh Ojha |
| 12 |
[GO] |
2020―Aug―08 |
Epigallocatechin gallate and theaflavin gallate interaction in
SARS-CoV
-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study |
Smarajit Maiti, Amrita Banerjee |
| 13 |
[GO] |
2020―Aug―05 |
Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers |
Irena Voinsky, David Gurwitz |
| 14 |
[GO] |
2020―Jul―31 |
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19 |
Suman Rohilla |
| 15 |
[GO] |
2020―Jul―14 |
Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirus-2 proteome |
Aatika Sadia, Muhammad Asim Raza Basra |
| 16 |
[GO] |
2020―Jul―13 |
TWIRLS
, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via
ACE2 |
Xiaoyang Ji, Wenting Tan, Chunming Zhang, Yubo Zhai, Yiching Hsueh, Zhonghai Zhang, Chunli Zhang, Yanqiu Lu, Bo Duan, Guangming Tan, Renhua Na, Guohong Deng, Gang Niu |
| 17 |
[GO] |
2020―Jul―07 |
Revisiting potential druggable targets against
SARS-CoV
-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review |
Abdullah Al Mamun Sohag, Md Abdul Hannan, Sadaqur Rahman, Motaher Hossain, Mahmudul Hasan, Md Kawsar Khan, Amena Khatun, Raju Dash, Md Jamal Uddin |
| 18 |
[GO] |
2020―Apr―27 |
Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |
Soltan A. Ebrahimi |
| 19 |
[GO] |
2020―Apr―18 |
Response to recent commentaries regarding the involvement of a
ngiotensin-converting
enzyme 2 (
ACE2
) and
renin-angiotensin
system blockers in
SARS-CoV
-2 infections |
Robert C. Speth |
| 20 |
[GO] |
2020―Mar―30 |
COVID-19 treatment by repurposing drugs until the vaccine is in sight |
Mrudula Phadke, Sujata Saunik |
| 21 |
[GO] |
2020―Mar―04 |
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics |
David Gurwitz |
